
Sign up to save your podcasts
Or


Developing non-traditional antibiotics promises novel strategies to combat multidrug-resistant organisms but would they work? Are they feasible to develop?
Topics discussed: • The notion of non-traditional antibiotics as potential therapeutics against MDR organisms • Increasing our understanding on the clinical efficacy of non-traditional antibiotics • Regulatory pathways for approval of such compounds
Guest: Dr. John Rex, Chief Medical Officer, F2G Ltd. | Editor-in-Chief, AMR.solutions
Visit https://aac.asm.org to browse issues and/or submit a manuscript.
By American Society for Microbiology4.6
2424 ratings
Developing non-traditional antibiotics promises novel strategies to combat multidrug-resistant organisms but would they work? Are they feasible to develop?
Topics discussed: • The notion of non-traditional antibiotics as potential therapeutics against MDR organisms • Increasing our understanding on the clinical efficacy of non-traditional antibiotics • Regulatory pathways for approval of such compounds
Guest: Dr. John Rex, Chief Medical Officer, F2G Ltd. | Editor-in-Chief, AMR.solutions
Visit https://aac.asm.org to browse issues and/or submit a manuscript.

90,952 Listeners

43,628 Listeners

2,060 Listeners

28 Listeners

453 Listeners

129 Listeners

38 Listeners

522 Listeners

12 Listeners

20 Listeners

4 Listeners

822 Listeners

111,848 Listeners

367 Listeners

170 Listeners

185 Listeners

4 Listeners

36 Listeners

87 Listeners

3 Listeners

10 Listeners

1,175 Listeners